SCHEMBL2473041

SCHEMBL2473041

CCOC(=O)c1ccc(Cl)nn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.53
LMNA P02545 3/20 0.46
ALDH1A1 P00352 2/20 0.46
TSHR P16473 1/20 0.44
GABRA2 P47869 2/20 0.43
GABRB2 P47870 2/20 0.43
MAPT P10636 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
NOTUM Q6P988 1/20 0.43
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA7 P43166 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
ESR1 P03372 1/20 0.42
ESR2 Q92731 1/20 0.42
KMT2A Q03164 2/20 0.41
NPC1 O15118 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5642066 0.89 CYP1A2 (0.64) CYP1A2LMNAALDH1A1TSHRGABRA2
SCHEMBL7673847 0.83 TSHR (0.50) CYP1A2LMNAALDH1A1TSHRMAPT
SCHEMBL1645260 0.81 CYP1A2 (0.56) CYP1A2LMNAALDH1A1TSHRGABRA2
SCHEMBL13197220 0.81 CYP1A2 (0.56) CYP1A2LMNAALDH1A1TSHRGABRA2
SCHEMBL29524945 0.81 CYP1A2 (0.56) CYP1A2LMNAALDH1A1TSHRGABRA2
SCHEMBL29036215 0.80 GAA (0.42) CYP1A2LMNAALDH1A1TSHRMAPT
SCHEMBL5169193 0.80 CYP1A2 (0.55) CYP1A2LMNAALDH1A1TSHRGABRA2
SCHEMBL29552833 0.79 MAPK1 (0.47) CYP1A2LMNAALDH1A1TSHRMAPT
SCHEMBL474101 0.79 MAPK1 (0.47) CYP1A2LMNAALDH1A1TSHRMAPT
SCHEMBL24880489 0.79 CYP1A2 (0.53) CYP1A2LMNAALDH1A1TSHRGABRA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570634-B2 Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof INSILICO MEDICINE IP LIMITED (HK) 2026-03-10 US disclosed
EP-4626892-A1 ADENOSINE A2A AND A2B RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF Merck Sharp & Dohme LLC (US) 2025-10-08 EP disclosed
US-20250026754-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF INSILICO MEDICINE IP LTD (CN) 2025-01-23 US disclosed
CN-119053601-A Small molecule inhibitors of ubiquitin-specific protease 1 (USP 1) and uses thereof 英矽智能科技知识产权有限公司 2024-11-29 CN disclosed
US-12145929-B2 Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same NEXTGEN BIOSCIENCE CO., LTD. (KR) 2024-11-19 US disclosed
CN-114981256-B Single-ring agonists of the interferon gene stimulator STING 斯克里普斯研究学院 2024-11-08 CN disclosed
US-20240327390-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2024-10-03 US disclosed
EP-4430050-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF Insilico Medicine IP Limited (HK) 2024-09-18 EP disclosed
US-20240279216-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME NEXTGEN BIOSCIENCE CO., LTD. (KR) 2024-08-22 US disclosed
CN-113412113-B Amino oxazinamides 豪夫迈·罗氏有限公司 2024-07-26 CN disclosed
EP-0733033-B1 PHARMACEUTICALLY ACTIVE SUBSTITUTED AROMATIC COMPOUNDS ZENECA LTD (GB) 1999-12-22 EP disclosed
EP-0918769-A1 SUBSTITUTED PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTI-BACTERIAL AGENTS AstraZeneca AB (SE) 1999-06-02 EP disclosed
EP-0912554-A1 INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1999-05-06 EP disclosed
US-5843942-A Aromatic amino ethers as pain relieving agents ZENECA LIMITED (GB) 1998-12-01 US disclosed
US-5811459-A PAIN RELIEVERS ZENECA LIMITED (GB) 1998-09-22 US disclosed
WO-1998001446-A1 SUBSTITUTED PIPERAZINYL-PHENYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTI-BACTERIAL AGENTS ZENECA LIMITED (GB) 1998-01-15 WO disclosed
WO-1997048699-A1 INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM PLC (GB) 1997-12-24 WO disclosed
US-5340808-A Fused pyridazinoquinazolone derivatives as neurotrophic agents WARNER LAMBERT COMPANY (US) 1994-08-23 US disclosed
WO-1994011373-A1 PYRIDAZINOQUINAZOLONE DERIVATIVES AS NEUROTROPHIC AGENTS WARNER-LAMBERT COMPANY (US) 1994-05-26 WO disclosed
US-5250548-A Treating hypertension, heart failure ABBOTT LABORATORIES (US) 1993-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327390-A1 SUBSTITUTED NITROGEN CONTAINING COMPOUNDS NR0B1, GRK1, GRIN1 CYP1A2 1414/4885LMNA 610/4885ALDH1A1 2289/4885
US-20240279216-A1 NOVEL PIPERIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOTAXIN COMPRISING SAME ENPP2, UACA, ITCH CYP1A2 4675/4885LMNA 4393/4885ALDH1A1 3067/4885
US-20250026754-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF USP1, USP2, USP28 CYP1A2 3750/4885LMNA 3361/4885ALDH1A1 1562/4885
US-12145929-B2 Piperidine derivative and pharmaceutical composition for inhibiting autotaxin comprising same ENPP2, UACA, ACAT2 CYP1A2 4578/4885LMNA 4317/4885ALDH1A1 2751/4885
US-12570634-B2 Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof USP1, USP2, USP3 CYP1A2 1101/4885LMNA 4102/4885ALDH1A1 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.